At the 2nd Congress of the European Academy of Neurology (EAN), held in Copenhagen, Denmark, from May 28–31 2016, Giovanni Frisoni, MD, from Geneva University Hospital, Geneva, Switzerland, discusses the current clinical use of biomarkers in Alzheimer’s disease as well as the development of biomarkers for early diagnosis, particularly in asymptomatic individuals that will lead to the application of personalized therapies.
